These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34081375)

  • 1. Valganciclovir for the treatment of cytomegalovirus infections in pediatric intestinal transplant recipients: A case series.
    Henry M; Leick M; Florescu DF; Keck M
    Pediatr Transplant; 2021 Sep; 25(6):e14034. PubMed ID: 34081375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk factors for the development of cytomegalovirus viremia in a steroid sparing liver transplant center.
    Viehl E; Lichvar A; Chan C; Choi D
    Transpl Infect Dis; 2022 Aug; 24(4):e13867. PubMed ID: 35604549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of CMV-specific cytotoxic T cells (CMV-Tc) in pediatric renal transplant recipients with CMV viremia.
    Pizzo H; Shin B; Garrison J; Huang E; Malekzadeh M; Jordan SC; Puliyanda D; Toyoda M
    Pediatr Transplant; 2021 Dec; 25(8):e14119. PubMed ID: 34390094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
    JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.
    Paulsen G; Cumagun P; Mixon E; Fowler K; Feig D; Shimamura M
    Pediatr Transplant; 2019 May; 23(3):e13382. PubMed ID: 30786115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis.
    Das BB; Prusty BK; Niu J; Sue PK
    Pediatr Transplant; 2020 Dec; 24(8):e13750. PubMed ID: 32573886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A national survey of valganciclovir dosing strategies in pediatric organ transplant recipients.
    Shaikh S; Jasiak-Panek N; Park JM
    Clin Transplant; 2018 Sep; 32(9):e13369. PubMed ID: 30076649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
    Korneffel K; Mitro G; Buschor K; Rees M; Ortiz J
    Transpl Immunol; 2019 Oct; 56():101226. PubMed ID: 31344441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
    Maertens J; Cordonnier C; Jaksch P; Poiré X; Uknis M; Wu J; Wijatyk A; Saliba F; Witzke O; Villano S
    N Engl J Med; 2019 Sep; 381(12):1136-1147. PubMed ID: 31532960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
    Jorgenson MR; Descourouez JL; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
    Transpl Infect Dis; 2021 Aug; 23(4):e13693. PubMed ID: 34309158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced dosing versus full dosing valganciclovir for prophylaxis of cytomegalovirus in high-risk abdominal transplant recipients.
    Kreiser ML; Dupuis R; Szempruch KR; Chargualaf LM
    Clin Transplant; 2023 Oct; 37(10):e15041. PubMed ID: 37256906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
    Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
    Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
    Rho E; Näf B; Müller TF; Wüthrich RP; Schachter T; von Moos S
    Clin Transplant; 2021 Nov; 35(11):e14401. PubMed ID: 34181768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ganciclovir-Resistant Cytomegalovirus Infection in Abdominal Solid Organ Transplant Recipients: Case Series and Review of the Literature.
    Rolling KE; Jorgenson MR; Descourouez JL; Mandelbrot DA; Redfield RR; Smith JA
    Pharmacotherapy; 2017 Oct; 37(10):1258-1271. PubMed ID: 28699311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study.
    Herrera S; Khan B; Singer LG; Binnie M; Chaparro C; Chow CW; Martinu T; Tomlinson G; Keshavjee S; Husain S; Tikkanen JM
    Transpl Infect Dis; 2020 Aug; 22(4):e13277. PubMed ID: 32170813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir.
    Bedel AN; Hemmelgarn TS; Kohli R
    Liver Transpl; 2012 Mar; 18(3):347-54. PubMed ID: 22139888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of a Weight-based Dosing Regimen of Valganciclovir for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients.
    Pappo A; Peled O; Berkovitch M; Bilavsky E; Rom E; Amir J; Krause I; Yarden-Bilavsky H; Scheuerman O; Ashkenazi-Hoffnung L
    Transplantation; 2019 Aug; 103(8):1730-1735. PubMed ID: 31343571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
    BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of valganciclovir prophylaxis in high-risk (D+/R-) renal transplant recipients experiencing delayed graft function.
    Freedman SR; Ravichandran BR; Masters BM; Bromberg JS; Haririan A; Saharia KK; Heil EL; Sparkes T
    Transpl Infect Dis; 2019 Aug; 21(4):e13125. PubMed ID: 31165548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.
    Johansson I; Mårtensson G; Nyström U; Nasic S; Andersson R
    BMC Infect Dis; 2013 Dec; 13():582. PubMed ID: 24325216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.